{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:26:40Z","timestamp":1792168000093,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BioIncept LLC; ADI Foundation, Israel, the William and Karen Davidson Fund, Hermelin Brain Tumor Center, MI, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a progressive, lethal, X-linked disease of skeletal and cardiac muscles caused by mutations in the dystrophin gene. Loss of dystrophin leads to muscle fiber damage and impairment of satellite cell asymmetric division, which are essential for muscle regeneration. These processes ultimately result in muscle wasting and the replacement of the degenerating muscles by fibrogenic cells, a process that leads to the generation of fibrotic tissues. Preimplantation factor (PIF) is an evolutionary conserved 15-amino acid peptide secreted by viable mammalian embryos. Synthetic PIF (sPIF) reproduces the protective\/regenerative effects of the endogenous peptide in immune disorders and transplantation models. In this study, we demonstrated that sPIF treatment promoted mouse and human myoblast differentiation and inhibited the expression of collagen 1A1, collagen 1A2, and TGF-\u03b2 in DMD patient-derived myoblasts. Additionally, sPIF increased the expression of utrophin, a homolog of dystrophin protein. sPIF effects were mediated via the upregulation of lncRNA H19 and miR-675 and downregulation of let-7. sPIF also inhibited the expression of miR-21, a major fibrosis regulator. The administration of sPIF in mdx mice significantly decreased serum creatine kinase and collagen I and collagen IV expression in the diaphragm, whereas it increased utrophin expression in the diaphragm, heart and quadriceps muscles. In conclusion, sPIF promoted the differentiation of DMD myoblasts, increased utrophin expression via the H19\/miRNA-675\/let-7 pathway, and reduced muscle fibrosis possibly via the upregulation of miR-675 and inhibition of miR-21 expression. These findings strongly support pursuing sPIF as a potential therapeutic agent for DMD. Moreover, the completion of an sPIF phase I safety trial will further promote the use of sPIF for the treatment of muscular dystrophies.<\/jats:p>","DOI":"10.1038\/s41419-019-1307-9","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T10:03:08Z","timestamp":1548669788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["sPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19\/miR-675\/let-7 and miR-21 pathways"],"prefix":"10.1038","volume":"10","author":[{"given":"Daria","family":"Morgoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Berenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cazacu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Kazimirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan R.","family":"Barnea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"1307_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery, A. E. The muscular dystrophies. Lancet 359, 687\u2013695 (2002).","journal-title":"Lancet"},{"key":"1307_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 177\u2013189 (2010).","journal-title":"Lancet Neurol."},{"key":"1307_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0960-8966(93)90042-I","volume":"3","author":"KM Bushby","year":"1993","unstructured":"Bushby, K. M. et al. Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 3, 57\u201364 (1993).","journal-title":"Neuromuscul. Disord."},{"key":"1307_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","volume":"82","author":"DJ Blake","year":"2002","unstructured":"Blake, D. J., Weir, A., Newey, S. E. & Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291\u2013329 (2002).","journal-title":"Physiol. Rev."},{"key":"1307_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/nm.4006","volume":"21","author":"AC Keefe","year":"2015","unstructured":"Keefe, A. C. & Kardon, G. A new role for dystrophin in muscle stem cells. Nat. Med. 21, 1391\u20131393 (2015).","journal-title":"Nat. Med."},{"key":"1307_CR6","doi-asserted-by":"crossref","unstructured":"Bentzinger, C. F., Wang, Y. X. & Rudnicki, M. A. Building muscle: molecular regulation of myogenesis. Cold Spring Harb. Perspect. Biol. 4, 1\u201316 (2012).","DOI":"10.1101\/cshperspect.a008342"},{"key":"1307_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont, N. A. et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat. Med. 21, 1455\u20131463 (2015).","journal-title":"Nat. Med."},{"key":"1307_CR8","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1242\/jcs.086629","volume":"124","author":"A Uezumi","year":"2011","unstructured":"Uezumi, A. et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J. Cell. Sci. 124, 3654\u20133664 (2011).","journal-title":"J. Cell. Sci."},{"key":"1307_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich, S. et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418\u2013421 (2002).","journal-title":"Nature"},{"key":"1307_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier, C. R. et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med. 5, 1569\u20131585 (2013).","journal-title":"EMBO Mol. Med."},{"key":"1307_CR11","doi-asserted-by":"publisher","first-page":"H1550","DOI":"10.1152\/ajpheart.01253.2007","volume":"294","author":"KD Huebner","year":"2008","unstructured":"Huebner, K. D., Jassal, D. S., Halevy, O., Pines, M. & Anderson, J. E. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am. J. Physiol. Heart Circ. Physiol. 294, H1550\u2013H1561 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1307_CR12","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki, Y. et al. Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. USA. 109, 13763\u201313768 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1307_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. et al. Development of exon skipping therapies for Duchenne muscular dystrophy: A critical review and a perspective on the outstanding issues. Nucleic Acid. Ther. 27, 251\u2013259 (2017).","journal-title":"Nucleic Acid. Ther."},{"key":"1307_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs, R. C. et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 87, 2123\u20132131 (2016).","journal-title":"Neurology"},{"key":"1307_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1477-7827-9-63","volume":"9","author":"CW Stamatkin","year":"2011","unstructured":"Stamatkin, C. W. et al. PreImplantation Factor (PIF) correlates with early mammalian embryo development-bovine and murine models. Reprod. Biol. Endocrinol. 9, 63\u201374 (2011).","journal-title":"Reprod. Biol. Endocrinol."},{"key":"1307_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.rbmo.2011.06.009","volume":"23","author":"CW Stamatkin","year":"2011","unstructured":"Stamatkin, C. W. et al. Preimplantation factor negates embryo toxicity and promotes embryo development in culture. Reprod. Biomed. Online 23, 517\u2013524 (2011).","journal-title":"Reprod. Biomed. Online"},{"key":"1307_CR17","doi-asserted-by":"publisher","first-page":"32419","DOI":"10.18632\/oncotarget.16028","volume":"8","author":"LF Goodale","year":"2017","unstructured":"Goodale, L. F. et al. PreImplantation factor (PIF) protects cultured embryos against oxidative stress: relevance for recurrent pregnancy loss (RPL) therapy. Oncotarget 8, 32419\u201332432 (2017).","journal-title":"Oncotarget"},{"key":"1307_CR18","doi-asserted-by":"publisher","first-page":"e100263","DOI":"10.1371\/journal.pone.0100263","volume":"9","author":"ER Barnea","year":"2014","unstructured":"Barnea, E. R. et al. Insight into PreImplantation Factor (PIF*) mechanism for embryo protection and development: Target oxidative stress and protein misfolding (PDI and HSP) through essential RIPK binding site. PLoS One 9, e100263 (2014).","journal-title":"PLoS One"},{"key":"1307_CR19","doi-asserted-by":"publisher","first-page":"e0180642","DOI":"10.1371\/journal.pone.0180642","volume":"12","author":"NDi Simone","year":"2017","unstructured":"Simone, N. Di et al. Synthetic PreImplantation Factor (PIF) prevents fetal loss by modulating LPS induced inflammatory response. PLoS One 12, e0180642 (2017).","journal-title":"PLoS One"},{"key":"1307_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.382","volume":"7","author":"H Moindjie","year":"2016","unstructured":"Moindjie, H. et al. Preimplantation factor is an anti-apoptotic effector in human trophoblasts involving p53 signaling pathway. Cell Death Dis. 7, e2504 (2016).","journal-title":"Cell Death Dis."},{"key":"1307_CR21","doi-asserted-by":"publisher","first-page":"459.e1","DOI":"10.1016\/j.ajog.2010.03.024","volume":"202","author":"MJ Paidas","year":"2010","unstructured":"Paidas, M. J. et al. A genomic and proteomic investigation of the impact of preimplantation factor on human decidual cells. Am. J. Obstet. Gynecol. 202, 459.e1\u20138 (2010).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1307_CR22","doi-asserted-by":"publisher","first-page":"313.e1","DOI":"10.1016\/j.ajog.2012.07.017","volume":"207","author":"ER Barnea","year":"2012","unstructured":"Barnea, E. R. et al. PreImplantation Factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells. Am. J. Obstet. Gynecol. 207, 313. e1\u2013313. e11 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1307_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.imbio.2015.01.010","volume":"220","author":"ER Barnea","year":"2015","unstructured":"Barnea, E. R. et al. PIF direct immune regulation: Blocks mitogen-activated PBMCs proliferation, promotes TH2\/TH1 bias, independent of Ca2+. Immunobiology 220, 865\u2013875 (2015).","journal-title":"Immunobiology"},{"key":"1307_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.imbio.2016.02.004","volume":"221","author":"ER Barnea","year":"2016","unstructured":"Barnea, E. R. et al. PreImplantation factor (PIF) regulates systemic immunity and targets protective regulatory and cytoskeleton proteins. Immunobiology 221, 778\u2013793 (2016).","journal-title":"Immunobiology"},{"key":"1307_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rbmo.2012.09.017","volume":"26","author":"RG Roussev","year":"2013","unstructured":"Roussev, R. G. et al. Preimplantation factor inhibits circulating natural killer cell cytotoxicity and reduces CD69 expression: Implications for recurrent pregnancy loss therapy. Reprod. Biomed. Online 26, 79\u201387 (2013).","journal-title":"Reprod. Biomed. Online"},{"key":"1307_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12020-011-9438-5","volume":"40","author":"L Weiss","year":"2011","unstructured":"Weiss, L. et al. Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice. Endocrine 40, 41 (2011).","journal-title":"Endocrine"},{"key":"1307_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1160\/TH15-08-0640","volume":"115","author":"YC Chen","year":"2016","unstructured":"Chen, Y. C. et al. Preimplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids. Thromb. Haemost. 115, 1010\u20131024 (2016).","journal-title":"Thromb. Haemost."},{"key":"1307_CR28","doi-asserted-by":"publisher","first-page":"58975","DOI":"10.18632\/oncotarget.10635","volume":"7","author":"R Shainer","year":"2016","unstructured":"Shainer, R. et al. PreImplantation factor (PIF) therapy provides comprehensive protection against radiation induced pathologies. Oncotarget 7, 58975\u201358994 (2016).","journal-title":"Oncotarget"},{"key":"1307_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jns.2011.07.050","volume":"312","author":"L Weiss","year":"2012","unstructured":"Weiss, L. et al. Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J. Neurol. Sci. 312, 146\u2013157 (2012).","journal-title":"J. Neurol. Sci."},{"key":"1307_CR30","doi-asserted-by":"publisher","first-page":"13882","DOI":"10.1073\/pnas.1411674111","volume":"111","author":"M Mueller","year":"2014","unstructured":"Mueller, M. et al. PreImplantation factor promotes neuroprotection by targeting microRNA let-7. Proc. Natl. Acad. Sci. USA 111, 13882\u201313887 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1307_CR31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1038\/cdd.2015.55","volume":"22","author":"M Mueller","year":"2015","unstructured":"Mueller, M. et al. PreImplantation Factor bolsters neuroprotection via modulating Protein Kinase A and Protein Kinase C signaling. Cell Death Differ. 22, 2078\u20132086 (2015).","journal-title":"Cell Death Differ."},{"key":"1307_CR32","doi-asserted-by":"publisher","first-page":"21834","DOI":"10.18632\/oncotarget.15662","volume":"8","author":"G Migliara","year":"2017","unstructured":"Migliara, G. et al. PIF* promotes brain re-myelination locally while regulating systemic inflammation-clinically relevant multiple sclerosis M. smegmatis model. Oncotarget 8, 21834\u201321851 (2017).","journal-title":"Oncotarget"},{"key":"1307_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bbmt.2012.12.011","volume":"19","author":"Y Azar","year":"2013","unstructured":"Azar, Y. et al. PreImplantation Factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (Murine Model). Biol. Blood. Marrow Transplant. 19, 519\u2013528 (2013).","journal-title":"Biol. Blood. Marrow Transplant."},{"key":"1307_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10815-017-1051-y","volume":"35","author":"M Feichtinger","year":"2017","unstructured":"Feichtinger, M., Barnea, E. R., Nyachieo, A., Br\u00e4nnstr\u00f6m, M. & Kim, S. S. Allogeneic ovarian transplantation using immunomodulator preimplantation factor (PIF) as monotherapy restored ovarian function in olive baboon. J. Assist. Reprod. Genet. 35, 81\u201389 (2017).","journal-title":"J. Assist. Reprod. Genet."},{"key":"1307_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biomaterials.2018.04.055","volume":"174","author":"A Bier","year":"2018","unstructured":"Bier, A. et al. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy. Biomaterials 174, 67\u201378 (2018).","journal-title":"Biomaterials"},{"key":"1307_CR36","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.2174\/1381612820666141226095701","volume":"21","author":"Y Huang","year":"2015","unstructured":"Huang, Y., He, Y. & Li, J. MicroRNA-21: A central regulator of fibrotic diseases via various targets. Curr. Pharm. Des. 21, 2236\u20132242 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"1307_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gad.234419.113","volume":"28","author":"BK Dey","year":"2014","unstructured":"Dey, B. K., Pfeifer, K. & Dutta, A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev. 28, 491\u2013501 (2014).","journal-title":"Genes Dev."},{"key":"1307_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molcel.2013.08.027","volume":"52","author":"AN Kallen","year":"2013","unstructured":"Kallen, A. N. et al. The imprinted H19 lncRNA antagonizes Let-7 microRNAs. Mol. Cell 52, 101\u2013112 (2013).","journal-title":"Mol. Cell"},{"key":"1307_CR39","doi-asserted-by":"publisher","first-page":"e29376","DOI":"10.1371\/journal.pone.0029376","volume":"6","author":"U Basu","year":"2011","unstructured":"Basu, U. et al. Translational regulation of utrophin by miRNAs. PLoS One 6, e29376 (2011).","journal-title":"PLoS One"},{"key":"1307_CR40","doi-asserted-by":"publisher","first-page":"e0182676","DOI":"10.1371\/journal.pone.0182676","volume":"12","author":"MK Mishra","year":"2017","unstructured":"Mishra, M. K., Loro, E., Sengupta, K., Wilton, S. D. & Khurana, T. S. Functional improvement of dystrophic muscle by repression of utrophin: Let-7c interaction. PLoS One 12, e0182676 (2017).","journal-title":"PLoS One"},{"key":"1307_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-1-21","volume":"1","author":"CJ Mann","year":"2011","unstructured":"Mann, C. J. et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle 1, 21 (2011).","journal-title":"Skelet. Muscle"},{"key":"1307_CR42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0002-9440(10)63188-4","volume":"164","author":"Y Li","year":"2004","unstructured":"Li, Y. et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am. J. Pathol. 164, 1007\u20131019 (2004).","journal-title":"Am. J. Pathol."},{"key":"1307_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/joa.12443","volume":"228","author":"IC Barbin","year":"2016","unstructured":"Barbin, I. C. et al. Diaphragm degeneration and cardiac structure in mdx mouse: potential clinical implications for Duchenne muscular dystrophy. J. Anat. 228, 784\u2013791 (2016).","journal-title":"J. Anat."},{"key":"1307_CR44","doi-asserted-by":"crossref","first-page":"23249","DOI":"10.18632\/oncotarget.4021","volume":"6","author":"O Levi","year":"2015","unstructured":"Levi, O., Genin, O., Angelini, C., Halevy, O. & Pines, M. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy. Oncotarget 6, 23249\u201323260 (2015).","journal-title":"Oncotarget"},{"key":"1307_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1203\/01.PDR.0000145578.01985.D0","volume":"56","author":"JG Tidball","year":"2004","unstructured":"Tidball, J. G. & Wehling-Henricks, M. Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr. Res. 56, 831\u2013841 (2004).","journal-title":"Pediatr. Res."},{"key":"1307_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jcp.21895","volume":"221","author":"A Farini","year":"2009","unstructured":"Farini, A., Razini, P., Erratico, S., Torrente, Y. & Meregalli, M. Cell based therapy for duchenne muscular dystrophy. J. Cell. Physiol. 221, 526\u2013534 (2009).","journal-title":"J. Cell. Physiol."},{"key":"1307_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","volume":"179","author":"EP Hoffman","year":"2011","unstructured":"Hoffman, E. P. et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle. Am. J. Pathol. 179, 12\u201322 (2011).","journal-title":"Am. J. Pathol."},{"key":"1307_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pharmthera.2015.10.008","volume":"156","author":"ER Barnea","year":"2015","unstructured":"Barnea, E. R. et al. Immune regulatory and neuroprotective properties of preimplantation factor: From newborn to adult. Pharmacol. Ther. 156, 10\u201325 (2015).","journal-title":"Pharmacol. Ther."},{"key":"1307_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","volume":"31","author":"MD Grounds","year":"2008","unstructured":"Grounds, M. D., Radley, H. G., Lynch, G. S., Nagaraju, K. & De Luca, A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 31, 1\u201319 (2008).","journal-title":"Neurobiol. Dis."},{"key":"1307_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"T Wynn","year":"2008","unstructured":"Wynn, T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199\u2013210 (2008).","journal-title":"J. Pathol."},{"key":"1307_CR51","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","volume":"68","author":"I Desguerre","year":"2009","unstructured":"Desguerre, I. et al. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J. Neuropathol. Exp. Neurol. 68, 762\u2013773 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1307_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1083\/jcb.201105013","volume":"196","author":"E Ardite","year":"2012","unstructured":"Ardite, E. et al. PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J. Cell. Biol. 196, 163\u2013175 (2012).","journal-title":"J. Cell. Biol."},{"key":"1307_CR53","doi-asserted-by":"crossref","unstructured":"Reddy, S. et al. miR-21 is associated with fibrosis and right ventricular failure. JCI Insight 2, e91625 (2017).","DOI":"10.1172\/jci.insight.91625"},{"key":"1307_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep32231","volume":"6","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. TGF-\u03b21 promotes scar fibroblasts proliferation and transdifferentiation via up-regulating MicroRNA-21. Sci. Rep. 6, 32231 (2016).","journal-title":"Sci. Rep."},{"key":"1307_CR55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.molmed.2006.01.002","volume":"12","author":"P Miura","year":"2003","unstructured":"Miura, P. & Jasmin, B. J. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol. Med. 12, 122\u2013129 (2003).","journal-title":"Trends Mol. Med."},{"key":"1307_CR56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JC van Deutekom","year":"2003","unstructured":"van Deutekom, J. C. & van Ommen, G. J. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4, 774\u2013783 (2003).","journal-title":"Nat. Rev. Genet."},{"key":"1307_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.18632\/oncotarget.928","volume":"4","author":"A Bier","year":"2013","unstructured":"Bier, A. et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4, 665\u2013676 (2013).","journal-title":"Oncotarget"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1307-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:26:22Z","timestamp":1671207982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1307-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["1307"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1307-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eytan R. Barnea is the Chief Scientific Officer of BioIncept, LLC. Chaya Brodie received a grant from BioIncept, LLC. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"82"}}